{"id":"NCT04856891","sponsor":"Allakos Inc.","briefTitle":"A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis","officialTitle":"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AK002 in Patients With Moderately to Severely Active Eosinophilic Duodenitis Who Have an Inadequate Response With, Lost Response to, or Were Intolerant to Standard Therapies","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-05-20","primaryCompletion":"2022-06-14","completion":"2023-01-09","firstPosted":"2021-04-23","resultsPosted":"2024-01-02","lastUpdate":"2024-01-02"},"enrollment":94,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Eosinophilic Duodenitis","Eosinophilic Gastroenteritis"],"interventions":[{"type":"DRUG","name":"AK002","otherNames":["Lirentelimab"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"3.0 mg/kg of Lirentelimab (AK002)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a Phase 3, multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of lirentelimab (AK002) given monthly for 6 doses in adult patients with active eosinophilic duodenitis. Subjects who complete the randomized, double-blind, placebo-controlled treatment may have the option to receive 6 doses of open-label lirentelimab (AK002) through the OLE Period of the study.","primaryOutcome":{"measure":"Proportion of Tissue Eosinophil Responders at Week 24","timeFrame":"At Week 24","effectByArm":[{"arm":"3.0 mg/kg of Lirentelimab (AK002)","deltaMin":38,"sd":null},{"arm":"Placebo","deltaMin":2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":39,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":46},"commonTop":["Infusion related reaction","Corona virus infection","Hiatus hernia","Sinusitis","Diarrhea"]}}